Skip to content

News & Events

Andarix Pharmaceuticals Awarded Trademark for Tozaride by the US Patent and Trademark Office

Apr 26, 2019

Targeted therapy for cancer is based on personalized medicine approach SOMERVILLE, MA — March 2, 2019— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it has been granted the US trademark for Tozaride by the United States Patent and Trademark Office. About Tozaride Tozaride is…

Read More

Andarix Pharmaceuticals to Present at Neosynth Breast Cancer Conference

Apr 25, 2019

Targeted therapy for breast cancer is based on personalized medicine approach SOMERVILLE, MA — April 24, 2019— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present at the Neosynth Breast Cancer Conference in Boston MA on April 24-25th 2019. The presentation will address…

Read More

Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at the Society of Nuclear Medicine Meeting.

Oct 31, 2018

Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA — October 26, 2018— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration…

Read More

Andarix Pharmaceuticals to present at the CBI Basket and Umbrella Trials for Oncology Conference

Oct 25, 2018

Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA — October 18, 2018— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present strategies for broad-based or basket clinical trials in lung cancer. The presentation will take place at the…

Read More

Andarix Pharmaceuticals Selected to Present at the 6th JCA-AACR Special Joint Conference on Lung Cancer

Jul 23, 2018

The Andarix drug addresses the growing Lung Cancer problem in Asia SOMERVILLE, Mass.— July 10, 2018 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer has been selected to present a poster at the 6th JCA-AACR Special Joint Conference on lung cancer from July 10-12 in Kyoto,…

Read More

Andarix Pharmaceuticals to Present at the Metals to Medicine Gordon Research Conference

Jul 20, 2018

Targeting Lung Cancer in Rare Disease Patient Populations SOMERVILLE, MA— June 25, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing a targeted peptide therapies for hard to treat cancers, announced today that it will present a poster at the Metals in Medicine Gordon Research Conference .The conference will take place June 25-29…

Read More

Andarix Pharmaceuticals to Present at the Rare Disease Innovation Summit

Jul 19, 2018

Targeting Lung Cancer in Rare Disease Patient Populations SOMERVILLE, MA— June 19, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced today that its Chief Executive Officer, Chris Adams, will present at the Rare Disease Innovation Summit set to take place in Cambridge ,…

Read More

Andarix Pharmaceuticals to Present at Chinese Biopharmaceutical Association Conference, USA

Jul 18, 2018

Expanding Opportunities in Asia SOMERVILLE, MA— June 9, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced that its Chief Executive Officer, Chris Adams, will present at the Chinese Biopharmaceutical Association (CBA) USA conference. The CBA conference will take place on June 9, 2018…

Read More

Andarix Pharmaceuticals to Present at Regulatory Pathways Summit Conference

Feb 12, 2018

Personalized Medicine for Small Cell Lung Cancer SOMERVILLE, Mass.— January 29, 2018 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Innovative Regulatory Pathways Summit in Washington, DC. January 29-30, 2018. The conference will focus…

Read More

Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at international lung cancer meeting

Feb 9, 2018

Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA —January 8, 2018— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of…

Read More